Key Points
Excess weight is often linked with cardiovascular disease: It can lead to higher blood pressure or cholesterol, which increases the risk of heart attack and stroke..
Now, the makers of the popular weight-loss drug Wegovy are making a case for its use as a treatment option for diseases of the heart and blood vessels...
In a landmark trial of 17,604 overweight and obese patients with heart disease, weekly injections of semaglutidethe active ingredient in Wegovy and its twin Ozempicfor an average of 33 months reduced the risk of heart attack, stroke, and death from cardiovascular causes by 20 percent compared with a placebo group..
In a previous trial, semaglutide was shown to reduce cardiovascular risk in patients with diabetes who were overweight or obese..
Srividya Kidambi, an endocrinologist at the Medical College of Wisconsin, says the GLP-1 receptor seems to be present in heart tissue and blood vessels, albeit at low levels, and that semaglutide may be working directly on the cardiovascular system via this receptor..
You might be interested in
Weight loss medication benefits patients with heart failure, obesity: Research
02, Sep, 23Amsterdam [Netherlands], August 28 (ANI): According to new research presented at the ESC Congress 2023, semaglutide improves heart failure-related symptoms and physical function and results in greater weight loss compared to placebo in patients with heart failure with preserved ejection fraction (HFpEF) and obesity. Approximately half of patients with heart failure in the community have […]
Weight-loss drug can reverse heart failure symptoms, study finds
25, Aug, 23Semaglutide injections trigger ‘very large improvements’ in patients with hearts too stiff to fill properly
Ozempic and Wegovy Can Also Protect Your Heart
27, Sep, 23A new study shows that semaglutide reduces heart failure symptoms like fatigue and swelling by bringing down body weight.